Parameters | N = 188 |
---|---|
Age, median (IQR), year | 62.5 (51.0–79.0) |
BMI, median (IQR), kg/m2 | 25.4 (23.6–29.5) |
ASA score, median (IQR) | 2.0 (1.0–2.0) |
PSA, median (IQR), ng/ml | 28.85 (11.5–150.8) |
Prostate volume, median (IQR), cc | 38.6 (23.5–110.0) |
Biopsy Gleason score | Â |
 6 | 4 (2.1%) |
 7 | 58 (30.9%) |
 8 | 82 (43.6%) |
 ≥ 9 | 44 (23.4%) |
Clinical stage | Â |
 High-risk localized (≤ cT2c) | 54 (28.7%) |
 High-risk locally advanced | 134 (71.3%) |
  cT3a | 72 (38.3%) |
  ≥ cT3b | 62 (33.0%) |
  cN1 | 10 (5.3%) |
SHIM score, median (IQR) | 16.5 (7–24) |
IPSS score, median (IQR) | 14.5 (4–28) |
Charlson comorbidity index | Â |
 0 | 148 (78.7%) |
 1–2 | 35 (18.6%) |
  ≥ 3 | 5 (2.7%) |